48Q Stock Overview
A late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
X4 Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.28 |
| 52 Week High | US$1.35 |
| 52 Week Low | US$0.26 |
| Beta | 0.39 |
| 1 Month Change | -37.81% |
| 3 Month Change | -52.08% |
| 1 Year Change | -79.17% |
| 3 Year Change | -84.70% |
| 5 Year Change | -96.15% |
| Change since IPO | -96.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| 48Q | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -8.2% | 0.4% | -1.3% |
| 1Y | -79.2% | -14.3% | 13.1% |
Return vs Industry: 48Q underperformed the German Biotechs industry which returned -12.7% over the past year.
Return vs Market: 48Q underperformed the German Market which returned 13.3% over the past year.
Price Volatility
| 48Q volatility | |
|---|---|
| 48Q Average Weekly Movement | 30.1% |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.1% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: 48Q's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 48Q's weekly volatility has increased from 19% to 30% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 143 | Paula Ragan | www.x4pharma.com |
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases.
X4 Pharmaceuticals, Inc. Fundamentals Summary
| 48Q fundamental statistics | |
|---|---|
| Market cap | €48.44m |
| Earnings (TTM) | -€15.49m |
| Revenue (TTM) | €1.04m |
46.7x
P/S Ratio-3.1x
P/E RatioIs 48Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 48Q income statement (TTM) | |
|---|---|
| Revenue | US$1.12m |
| Cost of Revenue | US$495.00k |
| Gross Profit | US$628.00k |
| Other Expenses | US$17.39m |
| Earnings | -US$16.76m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 25, 2025
| Earnings per share (EPS) | -0.098 |
| Gross Margin | 55.92% |
| Net Profit Margin | -1,492.34% |
| Debt/Equity Ratio | 126.2% |
How did 48Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/24 04:15 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
X4 Pharmaceuticals, Inc. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Leah Rush Cann | Brookline Capital Markets |
| Arlinda Lee | Canaccord Genuity |
| Kristen Kluska | Cantor Fitzgerald & Co. |